✓ Translated by DotMD AI Clinical Council Source: The Journal of dermatological treatment • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #38880494 ↗

Phase III Randomized Trial: A multicenter, double-blind, randomized, parallel-group, active-controlled, phase 3 clinical trial to compare the effectiveness and safety of two botulinum toxin type A formulations for improving moderate to severe glabellar wrinkles in Asians (N = 276)

Original Paper Title: “A multicenter, double-blind, randomized, parallel-group, active-controlled, phase 3 clinical trial to compare the effectiveness and safety of two botulinum toxin type A formulations for improving moderate to severe glabellar wrinkles in Asians”

Elena Rostova (AI Quant) Rigor Score
93 / 100
Sample Size (Participants)
N = 276
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Safety evaluations indicated mild and transient adverse events, with no serious reactions observed. In conclusion, BMI2006 is an effective and safe BoNT-A for treating glabellar wrinkles with an expected duration of action between 8 and 12 weeks.
  • Study Design & Sample: Phase III Randomized Trial published in The Journal of dermatological treatment (N = 276 human participants).
  • Biostatistical Rigor Score: 93/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in The Journal of dermatological treatment (2024), this phase iii randomized trial evaluating 276 human participants investigated: Botulinum toxin type A (BoNT-A) was first isolated in 1946, and since then, several formulations have been developed and widely used to treat wrinkles by inducing muscle paralysis. Key clinical takeaway: Safety evaluations indicated mild and transient adverse events, with no serious reactions observed. In conclusion, BMI2006 is an effective and safe BoNT-A for treating glabellar wrinkles with an expected duration of action between 8 and 12 weeks.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (The Journal of dermatological treatment, 2024-12-15; N = 276; Rigor 93/100): Safety evaluations indicated mild and transient adverse events, with no serious reactions observed. In conclusion, BMI2006 is an effective and safe BoNT-A for treating glabellar wrinkles with an expected duration of action between 8 and 12 weeks.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: human-botulinum-neurotoxin-a-b-immune-globulin → Rx: botulinum-toxin-type-a → Rx: severe-congestion-and-cough-max-dextromethorphan-hbr-guaifenesin → Rx: night-time-severe-cold-and-cough-relief-acetaminophen-diphenhydramine → Condition: skin-aging → Condition: west-nile-virus → Condition: atopic-neurodermatitis →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 38880494: Phase III Randomized Trial: A multicenter, double-blind, randomized, parallel-group, active-controlled, phase 3 clinical trial to compare the effectiveness and safety of two botulinum toxin type A formulations for improving moderate to severe glabellar wrinkles in Asians (N = 276)

3 of 3 Free Questions Remaining